MedTrace Logo

Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures.

NCT05987033 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2026-01-28

Study results available
· View outcomes & findings →

Summary

Prospective, single arm, monocentric clinical study to test NVDX3 in patients suffering from distal radius fracture. NVDX3 will be implanted during a single surgical intervention.

Conditions

  • Distal Radius Fractures

Interventions

DRUG

NVDX3

NVDX3 is implanted during a single surgical intervention.

Sponsors & Collaborators

  • Novadip Biosciences

    lead INDUSTRY

Principal Investigators

  • Torsten Gerich, MD · Centre Hospitalier du Luxembourg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-08
Primary Completion
2024-12-19
Completion
2024-12-19

Countries

  • Luxembourg

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05987033 on ClinicalTrials.gov